美沙拉嗪联合双歧三联活菌对溃疡性结肠炎患者的治疗效果

Effect of Mesalazine Combined with Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules on Patients with Ulcerative Colitis

目的探究美沙拉嗪联合双歧三联活菌对溃疡性结肠炎患者的治疗效果。方法随机选取2019年8月—2021年8月江苏大学附属武进医院收治的溃疡性结肠炎患者90例作为研究对象,随机分为对照组(n=45)与观察组(n=45),对照组采用美沙拉嗪治疗,观察组在对照组基础上联合双歧三联活菌治疗。观察两组患者治疗前后炎性因子、Mayo评分、疾病活动指数(DAI)评分、不良反应发生率。结果治疗后,两组炎症因子均低于治疗前,且观察组低于对照组,差异有统计学意义(t=4.573、4.249、2.366、4.971,P<0.05)。治疗后,两组Mayo评分、DAI评分均降低,且观察组低于对照组,差异有统计学意义(t=3.098、6.690,P<0.05)。治疗后,观察组不良反应发生率为6.67%,低于对照组的26.67%,差异有统计学意义(χ^(2)=6.480,P=0.011)。结论美沙拉嗪联合双歧三联活菌可改善患者炎性因子水平,不良反应少,具有较高安全性。

Objective To investigate the therapeutic effect of Mesalazine combined with live combined bifidobacterium,lactobacillus and enterococcus capsules on patients with ulcerative colitis.Methods 90 patients with ulcerative colitis admitted to Wujin Hospital Affiliated to Jiangsu University from August 2019 to August 2021 were randomly selected as the study subjects and randomly divided into a control group(n=45)and an observation group(n=45).The control group was treated with Mesalazine,and the observation group combined with bifidobacterium triple therapy on the basis of the control group.The incidence of inflammatory factors,Mayo score,Disease Activity Index(DAI)score,and adverse reactions were observed in both groups before and after treatment.Results After treatment,the inflammatory factors in both groups were lower than before treatment,and the observation group was lower than the control group,the difference was statistically significant(t=4.573,4.249,2.366,4.971,P<0.05).After treatment,the Mayo score and DAI score of both groups decreased,and the observation group were lower than the control group,the difference was statistically significant(t=3.098,6.690,P<0.05).After treatment,the incidence of adverse reactions in the observation group was 6.67%,lower than 26.67%in the control group,the difference was statistically significant(χ^(2)=6.480,P=0.011).Conclusion Mesalazine combined with live combined bifidobacterium,lactobacillus and enterococcus capsules can improve inflammatory factors in patients with few adverse reactions and has a high safety profile.